A Phase II, Randomized, Multi-center Study, Assessing Value of Adding Everolimus (RAD001) to Trastuzumab as Preoperative Therapy of HER-2 Positive Primary Breast Cancer Amenable to Surgery

Trial Profile

A Phase II, Randomized, Multi-center Study, Assessing Value of Adding Everolimus (RAD001) to Trastuzumab as Preoperative Therapy of HER-2 Positive Primary Breast Cancer Amenable to Surgery

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms RADHER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results assessing predictive value of intratumoral signaling presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 14 Dec 2013 Results for the effect of treatment on biomarkers presented at the 36th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top